Literature DB >> 32745669

An especially high rate of radiation pneumonitis observed in patients treated with thoracic radiotherapy and simultaneous osimertinib.

Wenxiao Jia1, Hongbo Guo2, Wang Jing3, Xuquan Jing3, Ji Li3, Min Wang3, Jinming Yu4, Hui Zhu5.   

Abstract

Our study is the first to report an especially high rate of grade 2 or worse radiation pneumonitis in patients treated with thoracic radiotherapy and simultaneous Osimertinib, despite total lung V5, V20 and MLD seeming unlikely to induce radiation pneumonitis.
Copyright © 2020 The Author(s). Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Osimertinib; Radiation pneumonitis; Thoracic radiotherapy

Mesh：

Substances：

Year:  2020        PMID： 32745669     DOI： 10.1016/j.radonc.2020.07.051

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN： 0167-8140            Impact factor:   6.280


  9 in total

Review 1.  The oligometastatic spectrum in the era of improved detection and modern systemic therapy.

Authors:  Rohan R Katipally; Sean P Pitroda; Aditya Juloori; Steven J Chmura; Ralph R Weichselbaum
Journal:  Nat Rev Clin Oncol       Date:  2022-07-12       Impact factor: 65.011

Review 2.  Safety and Tolerability of Metastasis-Directed Radiation Therapy in the Era of Evolving Systemic, Immune, and Targeted Therapies.

Authors:  Elizabeth Guimond; Chiaojung Jillian Tsai; Ali Hosni; Grainne O'Kane; Jonathan Yang; Aisling Barry
Journal:  Adv Radiat Oncol       Date:  2022-07-14

3.  Symptomatic Radiation Pneumonitis in NSCLC Patients Receiving EGFR-TKIs and Concurrent Once-daily Thoracic Radiotherapy: Predicting the Value of Clinical and Dose-volume Histogram Parameters.

Authors:  Xuexi Yang; Ting Mei; Min Yu; Youling Gong
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2022-06-20

Review 4.  The Value of Radiotherapy for Advanced Non-Small Cell Lung Cancer With Oncogene Driver-Mutation.

Authors:  Jinfeng Cui; Li Li; Shuanghu Yuan
Journal:  Front Oncol       Date:  2022-05-13       Impact factor: 5.738

5.  Radiotherapy alters expression of molecular targets in prostate cancer in a fractionation- and time-dependent manner.

Authors:  Iris Eke; Molykutty J Aryankalayil; Michelle A Bylicky; Adeola Y Makinde; Lance Liotta; Valerie Calvert; Emanuel F Petricoin; Edward E Graves; C Norman Coleman
Journal:  Sci Rep       Date:  2022-03-03       Impact factor: 4.996

6.  Evaluation of Lung Tumor Target Volume in a Large Sample: Target and Clinical Factors Influencing the Volume Derived From Four-Dimensional CT and Cone Beam CT.

Authors:  Fengxiang Li; Tingting Zhang; Xin Sun; Yanlin Qu; Zhen Cui; Tao Zhang; Jianbin Li
Journal:  Front Oncol       Date:  2022-01-20       Impact factor: 6.244

Review 7.  Ablative Radiotherapy as a Strategy to Overcome TKI Resistance in EGFR-Mutated NSCLC.

Authors:  Jennifer Novak; Ravi Salgia; Howard West; Miguel A Villalona-Calero; Sagus Sampath; Terence Williams; Victoria Villaflor; Erminia Massarelli; Ranjan Pathak; Marianna Koczywas; Brittney Chau; Arya Amini
Journal:  Cancers (Basel)       Date:  2022-08-18       Impact factor: 6.575

8.  Overlap time is an independent risk factor of radiation pneumonitis for patients treated with simultaneous EGFR-TKI and thoracic radiotherapy.

Authors:  Wenxiao Jia; Qianqian Gao; Min Wang; Ji Li; Wang Jing; Jinming Yu; Hui Zhu
Journal:  Radiat Oncol       Date:  2021-02-23       Impact factor: 3.481

Review 9.  EGFR-mutated stage IV non-small cell lung cancer: What is the role of radiotherapy combined with TKI?

Authors:  Bailong Liu; Hui Liu; Yunfei Ma; Qiuhui Ding; Min Zhang; Xinliang Liu; Min Liu
Journal:  Cancer Med       Date:  2021-08-10       Impact factor: 4.452
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.